What question did this study set out to answer?

To review the cross-cellular inflammatory mechanisms, therapeutic targeting strategies, and clinical biomarker potential of CCL2 in rheumatoid arthritis.

August 16, 2026CellsOpen Access

CCL2 in Rheumatoid Arthritis: A Context-Dependent Cross-Cellular Node Serving as Biomarker and Therapeutic Target

View Full Paper

Ask AI

Bookmark

Authors

BSBowen ShiNanchang University KBKe BaiInstitute of Molecular Functional Materials RLRenping LiuNanchang University

Discussion

Member takes

Implication

Review reveals that CCL2 acts as a cross-cellular inflammatory hub in rheumatoid arthritis, suggesting utility as a biomarker despite mixed clinical trial efficacy.

Key Points

To review the cross-cellular inflammatory mechanisms, therapeutic targeting strategies, and clinical biomarker potential of CCL2 in rheumatoid arthritis.
Narrative synthesis of cellular, animal, and clinical studies evaluating CCL2 and the CCL2/CCR2 signaling axis in rheumatoid arthritis pathogenesis.
Analysis of therapeutic approaches targeting the CCL2 network and evaluation of human observational studies regarding CCL2 as a biomarker.
In vitro and animal models demonstrate that CCL2 promotes monocyte recruitment, synovial fibroblast activation, osteoclast-mediated bone remodeling, and vascular changes.
Direct pharmacological inhibition of the CCL2/CCR2 axis exhibits biological activity experimentally but has failed to demonstrate consistent clinical efficacy in established rheumatoid arthritis.
Circulating CCL2 correlates with preclinical risk, disease activity, treatment response, and interstitial lung disease, though standardized diagnostic cut-offs are currently lacking.

Cite This Study

Shi et al. (2026) studied this question.

synapsesocial.com/papers/6a8179abf2fb91fc834aced4 https://doi.org/10.3390/cells15161461

View Full Paper

Ask AI

Bookmark

Implication

Review reveals that CCL2 acts as a cross-cellular inflammatory hub in rheumatoid arthritis, suggesting utility as a biomarker despite mixed clinical trial efficacy.

CCL2 in Rheumatoid Arthritis: A Context-Dependent Cross-Cellular Node Serving as Biomarker and Therapeutic Target

Discussion

Member takes

Implication

Key Points

Cite This Study

CCL2 in Rheumatoid Arthritis: A Context-Dependent Cross-Cellular Node Serving as Biomarker and Therapeutic Target

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider